<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> is a devastating disease with limited treatment options </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, we found that the peroxisome proliferator-activated receptor-gamma (PPARgamma) <z:chebi fb="4" ids="48705">agonists</z:chebi> <z:chebi fb="0" ids="9753">troglitazone</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> reduce injury and <z:mp ids='MP_0001845'>inflammation</z:mp> in a rat model of transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The mechanism of this protection is unclear, as these agents can act through PPAR-gamma activation or through PPAR-gamma-independent mechanisms </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we examined PPAR-gamma expression, DNA binding and transcriptional activity following <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, we used a PPAR-gamma <z:chebi fb="68" ids="48706">antagonist</z:chebi>, T0070907, to determine the role of PPAR-gamma during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Using immunohistochemical techniques and real-time PCR, we found low levels of PPAR-gamma <z:chebi fb="2" ids="33699">mRNA</z:chebi> and PPAR-gamma immunoreactivity in nonischemic brain; however, PPAR-gamma expression dramatically increased in ischemic neurons, peaking 24 h following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Interestingly, we found that in both vehicle- and <z:chebi fb="4" ids="48705">agonist</z:chebi>-treated brains, DNA binding was reduced in the ischemic hemisphere relative to the contralateral hemisphere </plain></SENT>
<SENT sid="7" pm="."><plain>Expression of a PPAR-gamma target gene, <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase, was also reduced in ischemic relative to nonischemic brain </plain></SENT>
<SENT sid="8" pm="."><plain>Both DNA binding and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase expression were increased by the addition of the PPAR-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Finally, we found that <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>-mediated protection after <z:hpo ids='HP_0001297'>stroke</z:hpo> was reversed by the PPAR-gamma <z:chebi fb="68" ids="48706">antagonist</z:chebi> T0070907 </plain></SENT>
<SENT sid="10" pm="."><plain>Interestingly, infarction size was also increased by T0070907 in the absence of PPAR-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi>, suggesting that endogenous PPAR-gamma ligands may mitigate the effects of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>